Close Menu

NEW YORK (GenomeWeb) – Biocept today priced its public offering of more than 4.9 million shares of common stock at $.68 per share.

Net proceeds from the offering, expected to close on or about Dec. 7, is anticipated to be $3 million, which will go toward working capital and other general corporate purposes, Biocept said. The firm noted that no warrants to purchase shares of its common stock will be issued to investors in connection with the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.